ES2553742T3 - Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina - Google Patents

Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina Download PDF

Info

Publication number
ES2553742T3
ES2553742T3 ES11746176.4T ES11746176T ES2553742T3 ES 2553742 T3 ES2553742 T3 ES 2553742T3 ES 11746176 T ES11746176 T ES 11746176T ES 2553742 T3 ES2553742 T3 ES 2553742T3
Authority
ES
Spain
Prior art keywords
dosage form
pharmaceutical dosage
fluor
pyran
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11746176.4T
Other languages
English (en)
Inventor
Nadja Grüning
Marc Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2553742(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2553742T3 publication Critical patent/ES2553742T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forma de dosificación farmacéutica para su uso en el tratamiento del dolor que contiene un agente farmacológicamente activo de acuerdo con la fórmula general (I)**Fórmula** donde R es -H o -CH3, o una sal fisiológicamente aceptable del mismo, y una formulación autoemulsionante; administrándose la forma de dosificación farmacéutica dos veces al día, una vez al día o con menos frecuencia.

Description

imagen1

Claims (1)

  1. imagen1
ES11746176.4T 2010-08-04 2011-08-04 Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina Active ES2553742T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37063410P 2010-08-04 2010-08-04
US370634P 2010-08-04
EP10008115 2010-08-04
EP10008115 2010-08-04
PCT/EP2011/003918 WO2012016703A2 (en) 2010-08-04 2011-08-04 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Publications (1)

Publication Number Publication Date
ES2553742T3 true ES2553742T3 (es) 2015-12-11

Family

ID=43446583

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11746176.4T Active ES2553742T3 (es) 2010-08-04 2011-08-04 Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina

Country Status (27)

Country Link
EP (1) EP2600838B1 (es)
JP (1) JP5792301B2 (es)
KR (1) KR101788535B1 (es)
CN (1) CN103153282B (es)
AR (1) AR082559A1 (es)
AU (1) AU2011287873B2 (es)
BR (1) BR112013004055A2 (es)
CA (1) CA2802767C (es)
CL (1) CL2012003584A1 (es)
CO (1) CO6640316A2 (es)
DK (1) DK2600838T3 (es)
EC (1) ECSP13012421A (es)
ES (1) ES2553742T3 (es)
HR (1) HRP20151289T1 (es)
HU (1) HUE025322T2 (es)
IL (1) IL223881A (es)
MX (1) MX2013000980A (es)
NZ (1) NZ604662A (es)
PE (1) PE20131108A1 (es)
PL (1) PL2600838T3 (es)
PT (1) PT2600838E (es)
RS (1) RS54438B1 (es)
RU (1) RU2589830C2 (es)
SI (1) SI2600838T1 (es)
TW (1) TWI522360B (es)
WO (1) WO2012016703A2 (es)
ZA (1) ZA201209501B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2600851T1 (en) 2010-08-04 2018-07-31 Gruenenthal Gmbh PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
TWI567077B (zh) * 2011-12-12 2017-01-21 歌林達有限公司 （１ｒ，４ｒ）－６’－氟－Ｎ，Ｎ－二甲基－４－苯基－４’，９’－二氫－３’Ｈ－螺－［環己烷－１，１’－吡喃並－［３，４，ｂ］吲哚］－４－胺鹽酸鹽之固體形式
HUE029806T2 (hu) * 2011-12-12 2017-03-28 Gruenenthal Gmbh (1R,4R)-6'-fluor-(N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-spiro-[ciklohexán-1,1'-pirano-[3,4,b]indol]-4-amin és kénsav szilárd formái
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
TW201642853A (zh) 2015-01-23 2016-12-16 歌林達有限公司 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）
EP3253374B1 (en) 2015-02-02 2018-11-28 ratiopharm GmbH Composition comprising cebranopadol in a dissolved form
AU2017226830B2 (en) 2016-02-29 2021-06-24 Grünenthal GmbH Titration of cebranopadol
EP3613747A1 (en) * 2018-08-24 2020-02-26 Grünenthal GmbH Crystalline forms of trans-6'-fluoro-n-methyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
RU2765946C1 (ru) * 2021-03-11 2022-02-07 Графт Полимер Айпи Лимитед Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
KR20250145673A (ko) 2023-02-15 2025-10-13 애드뉴리스 테라퓨틱스 인코포레이티드 통증 완화에 유용한 요법 및 조성물
WO2025008447A1 (en) * 2023-07-05 2025-01-09 Bayer Aktiengesellschaft Composition for use in agriculture
WO2026035694A1 (en) 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373994A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
JP2009514890A (ja) * 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz

Also Published As

Publication number Publication date
RS54438B1 (sr) 2016-06-30
KR101788535B1 (ko) 2017-10-20
IL223881A (en) 2017-01-31
HRP20151289T1 (hr) 2016-01-01
ZA201209501B (en) 2013-08-28
HK1183610A1 (en) 2014-01-03
HUE025322T2 (en) 2016-02-29
KR20130095270A (ko) 2013-08-27
JP5792301B2 (ja) 2015-10-07
CO6640316A2 (es) 2013-03-22
CA2802767C (en) 2019-08-13
AU2011287873B2 (en) 2014-09-25
RU2013109136A (ru) 2014-09-10
AU2011287873A1 (en) 2013-01-24
CN103153282B (zh) 2015-08-19
WO2012016703A3 (en) 2012-08-16
MX2013000980A (es) 2013-02-15
TWI522360B (zh) 2016-02-21
CN103153282A (zh) 2013-06-12
EP2600838A2 (en) 2013-06-12
DK2600838T3 (en) 2015-10-05
SI2600838T1 (sl) 2015-12-31
CA2802767A1 (en) 2011-12-09
AR082559A1 (es) 2012-12-19
PL2600838T3 (pl) 2016-02-29
BR112013004055A2 (pt) 2018-04-24
RU2589830C2 (ru) 2016-07-10
ECSP13012421A (es) 2013-03-28
JP2013532699A (ja) 2013-08-19
CL2012003584A1 (es) 2013-02-01
PT2600838E (pt) 2015-11-17
NZ604662A (en) 2014-08-29
PE20131108A1 (es) 2013-10-17
EP2600838B1 (en) 2015-09-16
TW201209059A (en) 2012-03-01
WO2012016703A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
ECSP13012422A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NOCICEPTIVO
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
EP2444072A3 (en) Non-mucoadhesive film dosage forms
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
NI201100154A (es) Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
UY31826A (es) Compuesto peptídico y su uso
ECSP11010941A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.